MHRA Implements Major Clinical Trial Reform with Mandatory IVD Assessment Starting April 2026
核心洞察
The UK's MHRA will require mandatory submission of in vitro diagnostic (IVD) and companion diagnostic details as part of clinical trial applications starting April 28, 2026, marking the biggest update to clinical trial laws in 20 years.
Trial sponsors must provide comprehensive IVD documentation through the CTIMP submission package, including analytical performance studies and proper regulatory markings, with non-compliance preventing trial progression.
The new integrated review process combines IVD device assessment with existing clinical trial and ethics reviews to reduce duplication and increase transparency in trials using diagnostic technologies.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) is implementing sweeping changes to clinical trial regulations, requiring mandatory assessment of in vitro diagnostics (搜索) (IVDs) and companion diagnostics (搜索) (CDx) used in clinical studies. Starting April 28, 2026, trial sponsors must include comprehensive IVD documentation in their Clinical Trial of an Investigational Medicinal Product (CTIMP) submissions, with failure to comply preventing trials from proceeding.
Regulatory Framework Overhaul
"This will be the biggest update to clinical trial laws in 20 years, with a focus on improving patient safety, trial transparency, and ensuring that we provide a framework that is streamlined, agile and proportionate," explained Kingyin Lee, head of clinical trials at the MHRA, during a February 3 webinar.
The new requirements replace what Lee described as a "previous patchwork of guidelines" around IVDs and CDx devices used in clinical trials. The MHRA will integrate IVD device assessment into its existing combined review process, which currently coordinates MHRA and ethics reviews in parallel.
Submission Requirements and Compliance
Under the new framework, sponsors must provide detailed information about diagnostic devices through the Integrated Research Application System (IRAS). For IVDs that are UKCA or CE-marked and used according to their approved indications, sponsors must document this status in their CTIMP submission. Devices without such markings require a Health Institute Exemption (HIE). IVDs used at Northern Ireland sites must include European Union Medical Device Regulation (EU MDR) designation details.
Anthony Carter, low risk assessment manager at the MHRA, emphasized the critical nature of complete documentation: "If you do have the analytical performance study report, then you would submit this through IRAS. If you don't already have an analytical form of study, then we would ask you for the tabular summary instead."
The agency has established a seven-day validation window for IVD documentation. "Once we have this seven day validation window, we will be invalidating applications where the IVD documents are not present, because we need them upfront so we can perform this combined process," Carter stated.
Sponsors must also submit a cover letter clearly identifying IVD use in their trial package to "ensure proper routine for our system," according to Carter.
Expanding Role of Diagnostics in Clinical Research
Joseph Burt, head of diagnostics and general medical devices at the MHRA, highlighted the growing significance of diagnostic technologies in clinical research. "IVDs are starting to be used significantly in clinical trial settings, and the role of an IVD device is really to detect or to quantify certain biomarkers (搜索) to provide actionable clinical data for patient care," he explained.
IVDs serve multiple functions in clinical trials, including specimen examination to determine physiological or pathological states, assessing participants' predisposition to medical conditions, and predicting treatment response or monitoring therapeutic measures. Companion diagnostics (搜索) specifically identify patients most likely to benefit from particular therapies or assess medication reaction risks.
"It can be used for patient selection and stratification, to determine the patient's eligibility and stratification of participants based on certain biomarkers (搜索) associated with that clinical trial," Burt continued. "IVDs can also be used for monitoring treatment response, and increasingly, IVD devices support ongoing monitoring and treatment of safety and efficacy during clinical trial studies."
Assessment Criteria and Quality Standards
The MHRA's review process will evaluate the analytical performance of IVDs and CDx devices, focusing on their ability to "correctly, accurately and reliably" detect or measure specific biomarkers (搜索). This assessment compares device performance against evaluative reports provided in CTIMP submissions.
The evaluation encompasses three key performance metrics: sensitivity, measuring the device's ability to detect biomarker presence at the lowest concentration; specificity, assessing the device's ability to detect only the intended biomarker; and precision, evaluating the device's ability to consistently produce repeatable results when samples are tested multiple times under identical conditions.
Implementation Impact
Carter concluded that the new integrated structure aims to reduce duplication and increase transparency in clinical trials using IVDs. By combining IVD assessment with clinical trial evaluation and providing a single regulatory outcome, the MHRA expects to streamline the approval process while maintaining rigorous safety and efficacy standards.
The regulatory changes reflect the increasing integration of diagnostic technologies in modern clinical research, where biomarker-driven patient selection and treatment monitoring have become essential components of drug development and personalized medicine approaches.